预约演示
更新于：2025-03-30
Heparin Sodium
肝素钠
更新于：2025-03-30
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1944-05-19) |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C26H42N2NaO37S5 |
InChIKeyJRTRSJGZMRQDHI-UHFFFAOYSA-N |
CAS号- |
关联
159
项与 肝素钠 相关的临床试验NCT06714864
An Open-Label, Two-Arm (DefenCath® vs. Institutional Standard of Care) Study to Assess Safety and Time to Catheter-related Bloodstream Infections (CRBSI) in Subjects From Birth to Less Than 18 Years of Age With Kidney Failure Receiving Hemodialysis Via a Central Venous Catheter
NCT06662253
Anti-Xa Guided Dosing of Low Molecular Weight Heparin for Prevention of Venous Thromboembolism Following Traumatic Injury: a Multicentre Pilot Randomized Trial
NCT06512233
Dual Therapy Dilemma: Heparin Alone vs. Heparin-Aspirin Combo in Free Flap Survival
100 项与 肝素钠 相关的临床结果
登录后查看更多信息
100 项与 肝素钠 相关的转化医学
登录后查看更多信息
100 项与 肝素钠 相关的专利（医药）
登录后查看更多信息
5,415
项与 肝素钠 相关的文献（医药）2025-12-31ANNALS OF MEDICINE
Low-dose heparin sodium as a protective factor against bronchiolitis obliterans formation after adenovirus infection
Article
作者: Hu, Rong ; Cui, Lei ; Ding, Xiaofang ; Peng, Li ; Zhong, Lili ; Lin, Lin ; Huang, Han ; Liu, Silan ; Chen, Min
BACKGROUND:
Adenovirus (ADV) pneumonia in children is a significant contributor to the occurrence of post-infectious bronchiolitis obliterans (BO). Heparin sodium has known anti-inflammatory, immunomodulatory, and tissue repair properties. However, its role in treating BO after ADV infection remains unclear.
METHODS:
A retrospective analysis was conducted on 793 children diagnosed with ADV pneumonia and hospitalized in the southern region from January 2019 to December 2019. Among them, 307 cases were classified as single ADV pneumonia. We utilized directed acyclic graphs to analyze the causal relationships between various variables, which further helped us identify the independent and confounding variables for constructing our regression model. Propensity score matching (PSM) was also employed to control for confounding variables that could not be intervened in this study, ensuring baseline level equilibrium and correction. We utilized univariate logistic regression analysis to explore the factors influencing BO development after ADV pneumonia.
RESULTS:
Among the 793 children diagnosed with ADV pneumonia, 86 cases (10.84%) progressed to BO. The proportion of heparin use was higher in the non-BO group than in the BO group after PSM. The univariate regression analysis revealed that acute respiratory failure, neurological involvement and fibrinogen (FIB) were risk factors for the development of BO in ADV pneumonia cases (OR > 1, p < 0.05), but low-dose heparin sodium treatment and hemoglobin (OR < 1, p < 0.05) exhibited protective effects against BO formation. Among the 307 children with single ADV pneumonia (excluding confounding factors), 33 cases (10.75%) developed BO. The univariate regression analysis further indicated that fever duration, acute respiratory failure and FIB were risk factors for the development of BO in single ADV pneumonia (OR > 1, p < 0.05), while low-dose heparin sodium treatment (OR < 1, p < 0.05) was protective against BO formation after a single ADV pneumonia.
CONCLUSION:
Low-dose heparin sodium treatment may be a protective factor against the development of BO after ADV pneumonia infection.
2025-04-01SEMINARS IN THROMBOSIS AND HEMOSTASIS
Pharmacotherapy for Venous Thromboprophylaxis following Total Hip or Knee Arthroplasty: A Systematic Review and Network Meta-analysis
Review
作者: Ramanathan, Kollengode ; Li, Ruiqi ; Yong, Bryan Song Jun ; Ling, Ryan Ruiyang ; Poh, Jane Wenjin ; Ho, Sean Wei Loong ; Fan, Bingwen Eugene ; Rochwerg, Bram ; Arya, Roopen ; Tan, Chuen Seng
Abstract:
The optimal pharmacological prophylaxis for venous thromboembolism (VTE) after hip or knee arthroplasty is uncertain. We conducted a systematic review and network meta-analysis to compare the efficacy and safety of various medications. We searched multiple databases for randomized clinical trials (RCTs) comparing medications (including factor Xa inhibitors, factor IIa inhibitor, warfarin, unfractionated heparin [UFH], low-molecular-weight heparin [LMWH], aspirin, pentasaccharide) for VTE prophylaxis post-arthroplasty. Outcomes included any postoperative VTE identified with screening, major bleeding, and death. We used LMWH as the main comparator for analysis and performed trial sequential analysis (TSA) for each pairwise comparison. Certainty of evidence was assessed using GRADE (Grading of Recommendations, Assessments, Developments and Evaluations). We analyzed 70 RCTs (55,841 participants). Factor Xa inhibitors decreased postoperative VTE significantly compared with LMWH (odds ratio [OR]: 0.55, 95% confidence interval [CI]: 0.44–0.68, high certainty). Pentasaccharides probably reduce VTE (OR: 0.61, 95% CI: 0.36–1.02, moderate certainty), while the factor IIa inhibitor dabigatran may reduce VTE (OR: 0.75, 95% CI: 0.40–1.42, low certainty). UFH probably increases VTE compared with LMWH (OR: 1.31, 95% CI: 0.91–1.89, moderate certainty), and other agents like warfarin, aspirin, placebo, and usual care without thromboprophylaxis increase VTE (high certainty). Factor Xa inhibitors may not significantly affect major bleeding compared with LMWH (OR: 1.06, 95% CI: 0.81–1.39, low certainty). No medications had a notable effect on mortality compared with LMWH (very low certainty). TSA suggests sufficient evidence for the benefit of factor Xa inhibitors over LMWH for VTE prevention. Compared with LMWH and aspirin, factor Xa inhibitors are associated with reduced VTE after hip or knee arthroplasty, without an increase in bleeding and likely no impact on mortality.
2025-03-21Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
The dynamic of concentration of von Willebrand factor concentration in peracute and acute periods of cardioembolic stroke during heparin therapy
Article
作者: Avakyan, G.G. ; Koltsova, E.A. ; Shurdumova, M.Kh. ; Yasamanova, A.N. ; Petrova, E.A. ; Tran, M.D.
Objective. To study the prognostic value of von Willebrand factor (vWF) in peracute and acute periods of cardioembolic stroke (CES) in patients receiving unfractionated (UFH) and low molecular weight heparin (LMWH). Material and methods. Thirty patients with CES receiving UFH/LMWH and acetylsalicylic acid were examined. The comparison group included 15 patients with non-cardioembolic stroke without heparin therapy. On Days 2—3 and 7—10 from the disease onset, patients were evaluated using the NIHSS and HAS-BLED scales; also, brain CT, Doppler ultrasound, echocardiography, complete blood count and blood chemistry, vWF measurement, and induced platelet aggregation test with ristocetin, arachidonic acid, and collagen were performed. Results. During LMWH therapy in the peracute period, increased platelet aggregation with ristocetin (p=0.038) and vWF levels (p=0.017) were found versus the comparison group. A correlation between vWF level and platelet aggregation with collagen was identified (p=0.010, r=0.461). No inhibition of platelet function with ristocetin was observed during the entire period of therapy with both LMWH and UFH. During LMWH treatment, increased platelet activity with ristocetin was observed in the acute period, compared with patients receiving UFH (p=0.007). There were no significant differences in the change in the vWF levels in patients with and without hematuria. There was a correlation between the HAS-BLED score and hematuria in the semiquantitative analysis of erythrocytes in urine (p=0.041, r=0.375), as well as a correlation between the vWF levels and the ASPECT score (p=0.001, r=–0.576). Conclusion. The concomitant use of heparin with antiplatelet agents, particularly with aspirin in CES, enhances its anticoagulant activity and inhibits platelets in the test with arachidonic acid. Continued high ristocetin- and collagen-induced platelet aggregation supports the use of vasoprotective agents activating metabolic processes in the walls of blood vessels to correct persistent endothelial dysfunction.
100 项与 肝素钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 不稳定型心绞痛 | 泰国 | 2024-04-02 | |
| 非q波心肌梗死 | 泰国 | 2024-04-02 | |
| ST段抬高心肌梗死 | 泰国 | 2024-04-02 | |
| 血栓栓塞 | 美国 | 2011-07-21 | |
| 静脉血栓栓塞 | 美国 | 2011-07-21 | |
| 血栓形成 | 日本 | 2002-03-15 | |
| 血栓性静脉炎 | 澳大利亚 | 1991-08-16 | |
| 血管闭塞性疾病 | 澳大利亚 | 1991-08-16 | |
| 心房颤动 | 美国 | 1984-01-31 | |
| 导管堵塞 | 美国 | 1982-04-28 | |
| 弥散性血管内凝血 | 美国 | 1978-02-10 | |
| 凝血障碍 | 美国 | 1972-02-22 | |
| 栓塞 | 美国 | 1972-02-22 | |
| 肺栓塞 | 美国 | 1972-02-22 | |
| 静脉血栓形成 | 美国 | 1972-02-22 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 导管相关感染 | 临床3期 | 美国 | - | |
| 急性冠状动脉综合征 | 临床2期 | 美国 | 2009-07-01 | |
| 急性冠状动脉综合征 | 临床2期 | 法国 | 2009-07-01 | |
| 急性冠状动脉综合征 | 临床2期 | 德国 | 2009-07-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | 27 | Placebo (Placebo) | 積獵艱窪糧遞窪鏇觸夢(遞鏇築顧鹹憲鑰網鑰夢) = 遞構鑰遞鹹範鹽選鹹壓 衊獵壓夢淵蓋衊遞積艱 (窪膚願遞鏇鬱窪構艱鑰, 觸齋願簾繭願鬱範餘簾 ~ 窪鏇鹽遞簾築顧淵壓製) 更多 | - | 2024-10-15 | ||
(Heparin Sodium) | 積獵艱窪糧遞窪鏇觸夢(遞鏇築顧鹹憲鑰網鑰夢) = 鏇壓糧顧鹹網遞艱繭積 衊獵壓夢淵蓋衊遞積艱 (窪膚願遞鏇鬱窪構艱鑰, 膚積鹹窪網繭築繭鹽衊 ~ 膚築獵獵餘窪淵醖艱鏇) 更多 | ||||||
N/A | - | 遞願襯鏇醖願製餘壓壓(遞糧餘蓋獵鹽遞構築膚) = 壓獵簾鏇積襯襯蓋製製 窪憲鬱窪鑰簾鹹積艱衊 (鏇鏇觸獵襯鑰廠繭獵窪 ) 更多 | - | 2024-04-09 | |||
N/A | 41 | Hyperinsulinemic euglycemic clamp+Glycerol/Saline (Glycerol/Saline FAOD) | 範壓築網蓋製積艱鬱鹹(襯遞築鹹繭鬱鬱範遞醖) = 窪鬱醖鏇鹽獵範網齋積 醖夢製襯夢積醖構鹹製 (積襯鏇窪膚鑰夢願憲鏇, 244) 更多 | - | 2024-01-30 | ||
(Intralipid FAOD) | 範壓築網蓋製積艱鬱鹹(襯遞築鹹繭鬱鬱範遞醖) = 壓餘遞鑰選壓選顧糧膚 醖夢製襯夢積醖構鹹製 (積襯鏇窪膚鑰夢願憲鏇, 297) 更多 | ||||||
N/A | 195 | Full-dose LMWH | 夢醖範鹹夢獵憲獵鹽膚(範醖鏇獵廠繭鏇鹹餘淵) = 衊壓構觸製範窪鹹築憲 醖築製製壓構膚積齋廠 (鬱鏇糧鹹繭憲餘餘壓選 ) | - | 2023-12-11 | ||
Partial-dose LMWH | 夢醖範鹹夢獵憲獵鹽膚(範醖鏇獵廠繭鏇鹹餘淵) = 夢獵觸網觸鬱壓衊獵繭 醖築製製壓構膚積齋廠 (鬱鏇糧鹹繭憲餘餘壓選 ) | ||||||
N/A | 62 | 衊蓋構壓製遞網膚廠獵(鹹簾膚選鏇簾鏇衊窪襯) = 製淵遞選獵壓顧鏇構廠 鏇鹽築淵鹽衊醖簾憲膚 (膚鏇範構顧觸網廠觸網 ) | - | 2023-12-10 | |||
N/A | - | (No pharmacologic prophylaxis (NP)) | 遞積壓顧積積遞蓋壓餘(餘網廠選製醖選廠網鹹) = 夢夢獵襯鏇構積窪齋窪 鑰簾獵淵繭觸餘獵簾醖 (網鏇築選獵衊構簾願糧 ) 更多 | - | 2023-09-01 | ||
遞積壓顧積積遞蓋壓餘(餘網廠選製醖選廠網鹹) = 願窪鏇顧衊獵衊鬱製願 鑰簾獵淵繭觸餘獵簾醖 (網鏇築選獵衊構簾願糧 ) 更多 | |||||||
N/A | PF4 | 165 | 顧齋網糧觸膚憲遞餘顧(鬱襯鏇襯鬱築積糧憲夢) = 糧餘鹹鹹餘鹽窪醖築願 窪夢膚鏇鬱鬱顧積鬱窪 (夢獵膚鑰艱網選齋簾構, +301 ~ +406) | - | 2023-06-24 | ||
N/A | - | 6 | Heparin sodium (Hep) full dose | 夢鹹鑰膚網鹹範壓願糧(憲顧窪觸醖鹹網齋網糧) = 廠鬱蓋餘鹽鹽製鬱製醖 鏇獵範鑰簾糧襯網衊簾 (構築積壓餘構鏇窪窪壓 ) | 积极 | 2022-11-06 | |
Heparin sodium (Hep) 50% reduced dose | 夢鹹鑰膚網鹹範壓願糧(憲顧窪觸醖鹹網齋網糧) = 選醖淵簾襯鏇製壓範窪 鏇獵範鑰簾糧襯網衊簾 (構築積壓餘構鏇窪窪壓 ) | ||||||
N/A | - | 14 | 繭鏇糧簾壓齋範遞鑰齋(齋廠選顧廠蓋醖構鑰夢) = 壓鹽鏇鹽簾網選襯齋繭 艱餘鬱醖夢齋鬱製壓鑰 (鏇顧選鹹廠遞糧艱艱糧 ) 更多 | 积极 | 2022-09-07 | ||
N/A | - | - | 遞廠窪憲繭簾獵範鏇艱(鬱壓簾製蓋蓋築膚築襯) = 願鏇窪積糧積遞糧淵鹽 鏇醖觸願鹹夢壓夢願繭 (築簾齋廠餘廠構廠築淵 ) 更多 | - | 2022-08-27 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用